Vland Selected as the No. 2 Company in the “Top 10 Innovative Private Enterprises of Qingdao 2025”

‍‍‍‍‍‍

Recently, Qingdao Entrepreneurs Conference and the Meeting on Optimizing Business Environment were held, during which the 2025 Qingdao Top 100 Private Enterprises lists were officially released. Qingdao Vland Biotech Inc. was selected as one of the Top 10 Innovative Private Enterprises of Qingdao, ranking second.

According to Vland's 2025 semi-annual report, the company has consistently adhered to the concept of independent innovation, continuously improving its technological capabilities to enhance product quality, optimize product structure, and reduce production costs. In the first half of 2025, the company invested 9 million USD in R&D, accounting for 9.80% of its operating revenue—one of the highest levels in the industry.

Vland has established six technology centers and two key labs, and carries out R&D work based on eight national-level innovation platforms. In June 2025, the project "Creation and Industrial Application of Key Enzymes for Pulp and Paper Making" led by the company's wholly owned subsidiary Qingdao Vland Biotech Group Co., Ltd., won the First Prize of the Shandong Provincial Technological Invention Award. The company also participated in the project "Construction and Application of a Key Technology System for High-Value Bioprocessing of Aquatic Resources", which won the First Prize of the Shandong Provincial Science and Technology Progress Award.

In July 2025, Vland was recognized with the "Outstanding Contribution Award for High-Quality Development of Shandong's Private Economy" and was listed among the Top 100 Science and Technology Enterprises in China's Light Industry. As of the end of the reporting period, the company and its subsidiaries held 406 China authorized invention patents, 10 U.S. patents, 2 European patents, 28 PCT international applications, and 51 new veterinary drug certificates (including three Class I China national new veterinary drugs).

‍‍‍‍‍‍